After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

03/05/2015 - 3 minutes

Poxel continues to interest the market after its successful IPO in February 2015, where it has raised approximately €27M with an incredible jump of +100% on its third day as a public company. Imeglimin, its lead candidate, is a Type 2 diabetes treatment (licensed by Merck Serono) on the launch of Phase III.

This innovative compound is the first of a new class of oral antidiabetic agents called “glimins“. It basically decreases mitcohondrial respiration, meaning that it targets the key defect associated with all three organs implicated in the disease.

Clinical studies to date have proven Imeglimin to have an efficiency comparable to Metformin and with a better, placebo-like safety/tolerability profile. Metformin is the first-line drug of choice for treating type 2 diabetes. Unlike Imeglimin, Metformin works by suppressing glucose production by the liver. The average person with type 2 diabetes produces three times the normal amount of glucose. Metformin treatment reduces this by over one-third. The only problem with Metformin is that it is no longer effective for sensitive populations,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member